^
Association details:
| Biomarker: | HMGA2 overexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | alisertib (MLN8237) (Aurora kinase A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1572 / 20 - Antiproliferative activity of enzalutamide and alisertib in prostate cancer cells overexpressing HMGA2
Published date:
03/15/2023
Excerpt:
In this study, we treated LNCaP cells overexpressing HMGA2 with enzalutamide (1-30 µM) and alisertib (2.5-40 µM)…alisertib is more potent than enzalutamide in decreasing cell proliferation in prostate cancer cells expressing HMGA2.
